CanSinoBIO Reports Positive Primary Immunization Data From Phase II VLP-Polio Trial in Indonesia

CanSinoBIO reported positive primary immunization data from key groups in its Phase II VLP-Polio vaccine trial in Indonesia, supporting further development, according to The future of trading. Main on-site trial activities are complete, and development progress was presented at the 2026 WHO Global Polio Vaccine Consultation in Geneva.

CanSinoBIO's Phase II VLP-Polio Trial Results

CanSinoBIO is a Chinese biopharmaceutical company developing, manufacturing and commercializing innovative vaccines across five proprietary technology platforms, serving government immunization programs and private-pay markets in China and more than 15 international markets with six launched products including MCV4, PCV13, DTcP and COVID-19 vaccines.

The vaccine does not require infectious live poliovirus in production, reducing the risk of viral release during manufacturing. China's National Medical Products Administration granted clinical trial approval in July 2025. The Gates Foundation funds clinical research, manufacturing scale-up and combination-vaccine development.

The National Medical Products Administration released the "Toothpaste Classification Directory" on October 15, 2026, banning medical efficacy claims on toothpaste labels, according to Ifeng.

CanSinoBIO's Recent Approvals and Partnerships

According to akta.pro company records, CanSinoBIO received registration approval for MCV4 (Menhycia) in Argentina in June 2026, marking entry into South American markets and following prior approvals in Chinese Mainland, Hong Kong, Indonesia and other countries. In April 2026, China's NMPA granted NDA approval for Tripedia (Tripieza), the first three-component DTcP combined vaccine approved in China, opening the pertussis-containing combination vaccine segment after 16 years of internal R&D. The company's production capacity from existing production lines in its Tianjin facility is 280 million doses per year.

Earlier CanSinoBIO Regulatory Milestones

CanSino Biologics announced on June 25, 2026 that its MCV4 quadrivalent meningococcal conjugate vaccine (Menhycia®) received drug registration approval from Argentina's regulatory authority ANMAT, marking the company's expansion into the South American market, according to Gurufocus. CanSino Biologics announced that its New Drug Application for the Td5cp Adolescent and Adult vaccine has been formally accepted by China's National Medical Products Administration, Gurufocus reported in August 2026. CanSinoBIO CEO Xuefeng Yu attended the World Economic Forum's Sustainable Development Impact Meetings in New York on Sept. 21-24, The future of trading reported in September 2026.

What Comes Next for CanSinoBIO

CanSinoBIO reported H1 2026 revenue of RMB550 million, up 43.8% year on year, with overseas revenue of RMB152 million, according to Yicaiglobal. CEO Jeanne Wang said the company's next stage focuses on integrating innovation with market needs, including portfolio expansion and international partnerships.